接受那他珠单抗治疗的多发性硬化女性妊娠决策:I:胎儿风险
本研究收集2009至2015年间19个中心的多发性硬化女性妊娠数据,比较那他珠单抗暴露、未治疗及注射免疫调节剂治疗组的胎儿结局。多因素分析显示那他珠单抗暴露与自然流产相关(OR 3.9,95%CI 1.9-8.5,p<0.001),但自然流产率(17.4%)和重大先天畸形率(3.7%)均在普通人群预期范围内;那他珠单抗与干扰素-β暴露均与婴儿出生身长和体重较低相关(p<0.001)。作者认为先天畸形风险需进一步研究。
要点
- 那他珠单抗暴露与自然流产相关(OR 3.9,95%CI 1.9-8.5),但自然流产率17.4%在普通人群预期范围内。
- 重大先天畸形率为3.7%,作者认为先天畸形风险需进一步研究。
- 那他珠单抗与干扰素-β暴露均与婴儿出生身长和体重较低相关(p<0.001)。
核心结论
- 那他珠单抗妊娠暴露至孕12周与自然流产风险增加相关,但自然流产率仍在普通人群预期范围内,先天畸形风险需进一步研究。
- 考虑到那他珠单抗停药后疾病复发风险高,作者认为可在严格监测受孕的情况下继续那他珠单抗并计划妊娠。
研究设计与样本
- 2009至2015年间收集19个参与中心的多发性硬化女性妊娠数据,共83名女性的92次妊娠。
- 与未治疗患者及接受注射免疫调节剂治疗患者的妊娠数据比较,并与意大利人群报告率比较,采用多因素logistic和线性回归模型。
主要发现
- 多因素分析中,那他珠单抗暴露与自然流产相关(OR 3.9,95%CI 1.9-8.5,p<0.001)。
- 自然流产率为17.4%,在普通人群预期范围内。
- 重大先天畸形率为3.7%,在普通人群预期范围内。
- 那他珠单抗和干扰素-β暴露均与婴儿出生身长和体重较低相关(p<0.001)。
关键数值与推荐
- 本研究提供III级证据:多发性硬化女性中,那他珠单抗暴露较干扰素-β暴露或未治疗增加自然流产风险(OR 3.9,95%CI 1.9-8.5)。
临床怎么用
- 作者认为,考虑到那他珠单抗停药后疾病复发风险高,可在严格监测受孕的情况下继续那他珠单抗并计划妊娠。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis (MS), with a specific focus on spontaneous abortion (SA) and congenital anomalies (CA). METHODS: Data of all pregnancies occurring between 2009 and 2015 in patients with MS treated with natalizumab and referring to 19 participating sites were collected and compared with those of pregnancies in untreated patients and patients treated with injectable immunomodulatory agents. Rates of SA and CA were also compared with those reported in the Italian population. Multivariable logistic and linear regression models were performed. RESULTS: A total of 92 pregnancies were tracked in 83 women. In the multivariable analysis, natalizumab exposure was associated with SA (odds ratio [OR] 3.9, 95% confidence interval [CI] 1.9-8.5, p < 0.001). However, the rate of SA (17.4%) was within the estimates for the general population, as well as the rate of major CA (3.7%). Moreover, exposure to natalizumab and interferon-β (IFN-β) was associated with lower length and weight of the babies (p < 0.001). CONCLUSION: Our results showed that natalizumab exposure to up 12 weeks of gestation is associated with an increased risk of SA, although within the limits expected in the general population, whereas the risk of CA needs further investigation. Taking into account the high risk of disease reactivation after natalizumab suspension, pregnancy could be planned continuing natalizumab while strictly monitoring conception. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in women with MS, natalizumab exposure increases the risk of spontaneous abortion as compared to IFN-β-exposed or untreated patients (OR 3.9, 95% CI 1.9-8.5).
引用
- Portaccio E, Annovazzi P, Ghezzi A, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018. PMID: 29438046. doi:10.1212/WNL.0000000000005067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。